PT3689379T - Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico - Google Patents

Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico

Info

Publication number
PT3689379T
PT3689379T PT201568151T PT20156815T PT3689379T PT 3689379 T PT3689379 T PT 3689379T PT 201568151 T PT201568151 T PT 201568151T PT 20156815 T PT20156815 T PT 20156815T PT 3689379 T PT3689379 T PT 3689379T
Authority
PT
Portugal
Prior art keywords
adrenerg
corticoid
anticholinergic
beta
preparing
Prior art date
Application number
PT201568151T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3689379(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PT3689379T publication Critical patent/PT3689379T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT201568151T 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico PT3689379T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16

Publications (1)

Publication Number Publication Date
PT3689379T true PT3689379T (pt) 2021-09-24

Family

ID=54548063

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201568151T PT3689379T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico
PT168019842T PT3377109T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT168019842T PT3377109T (pt) 2015-11-16 2016-11-14 Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico

Country Status (31)

Country Link
US (3) US10086003B2 (enExample)
EP (2) EP3377109B1 (enExample)
JP (1) JP6942126B2 (enExample)
KR (1) KR20180082442A (enExample)
CN (1) CN108348614B (enExample)
AR (1) AR106687A1 (enExample)
AU (1) AU2016357988B2 (enExample)
CA (1) CA3005291C (enExample)
CL (1) CL2018001297A1 (enExample)
CO (1) CO2018005139A2 (enExample)
DK (2) DK3377109T3 (enExample)
EA (1) EA037346B1 (enExample)
ES (2) ES2789365T3 (enExample)
GE (2) GEP20207178B (enExample)
HR (2) HRP20211599T1 (enExample)
HU (2) HUE050343T2 (enExample)
IL (1) IL259327B (enExample)
MA (1) MA52437A (enExample)
MX (1) MX377113B (enExample)
MY (1) MY198321A (enExample)
PE (1) PE20181377A1 (enExample)
PH (1) PH12018501023A1 (enExample)
PL (2) PL3689379T3 (enExample)
PT (2) PT3689379T (enExample)
SA (1) SA518391574B1 (enExample)
SG (2) SG10201912090UA (enExample)
SI (2) SI3689379T1 (enExample)
TW (1) TWI729025B (enExample)
UA (1) UA125173C2 (enExample)
WO (1) WO2017085007A1 (enExample)
ZA (1) ZA201803167B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206619A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US11304901B2 (en) * 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869B (zh) * 2023-09-27 2026-05-12 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba

Also Published As

Publication number Publication date
ES2789365T3 (es) 2020-10-26
GEAP201614782A (enExample) 2020-04-27
TW201722403A (zh) 2017-07-01
CA3005291A1 (en) 2017-05-26
UA125173C2 (uk) 2022-01-26
SI3377109T1 (sl) 2020-07-31
WO2017085007A1 (en) 2017-05-26
AU2016357988B2 (en) 2021-12-16
BR112018009811A8 (pt) 2019-02-26
US10959944B2 (en) 2021-03-30
MX2018005979A (es) 2018-08-29
SI3689379T1 (sl) 2021-11-30
TWI729025B (zh) 2021-06-01
PH12018501023B1 (en) 2018-12-17
EP3377109A1 (en) 2018-09-26
JP6942126B2 (ja) 2021-09-29
HUE056402T2 (hu) 2022-02-28
CA3005291C (en) 2024-01-16
DK3689379T3 (da) 2021-09-06
KR20180082442A (ko) 2018-07-18
MA52437A (fr) 2021-05-05
CN108348614A (zh) 2018-07-31
PL3377109T3 (pl) 2020-09-21
GEP20207178B (en) 2020-11-10
US10786451B2 (en) 2020-09-29
PT3377109T (pt) 2020-05-13
AR106687A1 (es) 2018-02-07
AU2016357988A1 (en) 2018-05-31
ES2890409T3 (es) 2022-01-19
HUE050343T2 (hu) 2020-11-30
US10086003B2 (en) 2018-10-02
IL259327B (en) 2020-11-30
HRP20211599T1 (hr) 2022-01-07
PH12018501023A1 (en) 2018-12-17
EP3689379A1 (en) 2020-08-05
HK1256859A1 (zh) 2019-10-04
EP3377109B1 (en) 2020-03-04
EA037346B1 (ru) 2021-03-16
JP2018537453A (ja) 2018-12-20
EA201890967A1 (ru) 2018-12-28
MX377113B (es) 2025-03-07
SA518391574B1 (ar) 2021-06-13
HRP20200571T1 (hr) 2020-07-10
US20200360278A1 (en) 2020-11-19
BR112018009811A2 (pt) 2018-11-13
EP3689379B1 (en) 2021-08-11
PE20181377A1 (es) 2018-09-05
CL2018001297A1 (es) 2018-08-10
NZ742473A (en) 2024-11-29
PL3689379T3 (pl) 2021-12-13
CO2018005139A2 (es) 2018-08-10
IL259327A (en) 2018-07-31
US20190021994A1 (en) 2019-01-24
CN108348614B (zh) 2021-09-21
MY198321A (en) 2023-08-24
GEAP202014782A (en) 2020-04-27
DK3377109T3 (da) 2020-04-20
SG10201912090UA (en) 2020-02-27
US20170136034A1 (en) 2017-05-18
ZA201803167B (en) 2019-07-31
SG11201804048WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PT3620176T (pt) Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
BR112016021834A2 (pt) Copolímero de propileno heteroplástico, processo para preparação de um copolímero de propileno heteroplástico, e, artigo
BR112016017175A2 (pt) Embalagem para acondicionamento de um artigo, e método para formar uma embalagem
PT3393744T (pt) Método para formar um artigo
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
PT3019153T (pt) Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
PT3024833T (pt) Novos derivados de indolizina, o seu processo de preparação e as composições farmacêuticas que os contêm
BR112016011575A2 (pt) processo para preparação de uma composição de revestimento antirreflexiva e um revestimento poroso feito da mesma.
BR112016026212A2 (pt) Processo para preparar cianidrina contendo fósforo
BR112014026564A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
ZA201803167B (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
BR112018002930A2 (pt) processo para preparação de um composto.
BR112017025267A2 (pt) recipiente e invólucro seletivamente formado e ferramentas e método associado para fornecer os mesmos
BR112016027607A2 (pt) poliuretano sililado, processo para preparação de um poliuretano sililado, formulação, composição, uso de um poliuretano sililado, e, produto
BR112016009727A2 (pt) processo para a preparação de uma mistura de eteramina, e, composição
BR112016027819A2 (pt) Processo de preparação de derivados de tiazole
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
PT3180295T (pt) Processo para rápida humificação e bioestabilização
BR112016015379A2 (pt) Processo para preparar um óxido de alquileno
BR112016027507A2 (pt) Método para a preparação de ácido (s)-2- acetiloxipropiônico e seus derivados
PT3271368T (pt) Novos derivados de fosfinano e de azafosfinano, o respetivo processo de produção e as composições farmacêuticas que os contêm
BR112018001313A2 (pt) composição de zolpidem e processo para preparar a mesma
CL2016002439A1 (es) Método para procesar arsénico y compuesto que contiene arsénico
PT3166594T (pt) Processo para preparar as formulações de inalação
FI20155021A7 (fi) Työkone ja työkoneen hytti